首页
400-620-6333
切换导航
搜索
基本信息
| 产品名称 | gemtuzumab ozogamicin |
|---|
产品属性
| CAS编号和信息 | Ab175546 |
|---|
数据库链接
| PubChem SID | 178103381 |
|---|---|
| IMGT/mAb-DB | 44 |
| Wikipedia | Gemtuzumab_ozogamicin |
靶标
| Target ID | 2601 | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 名称 | CD33 | ||||||||||||||||||||||||
| 缩写名 | SIGLEC3 | ||||||||||||||||||||||||
| 家族 | Other immune checkpoint proteins | ||||||||||||||||||||||||
| 别名 | KCa2.1 | ||||||||||||||||||||||||
| 基因和蛋白信息 |
|
||||||||||||||||||||||||
| Entrez Gene | 945 (Hs) , 12489 (Mm) , 690492 (Rn) | ||||||||||||||||||||||||
| UniProtKB | P20138 (Hs) , Q63994 (Mm) | ||||||||||||||||||||||||
| Ensembl Gene | ENSG00000105383 (Hs) , ENSMUSG00000004609 (Mm) , ENSRNOG00000037331 (Rn) | ||||||||||||||||||||||||
| RefSeq Nucleotide | NM_001111058 (Mm) , NM_001772 (Hs) | ||||||||||||||||||||||||
| RefSeq Protein | NP_001104528 (Mm) , NP_001763 (Hs) | ||||||||||||||||||||||||
| OMIM | 159590 (Hs) | ||||||||||||||||||||||||
| Protein GI | 130979981 (Hs) , 161484603 (Mm) | ||||||||||||||||||||||||
| DrugBank Target | P20138 (Hs) | ||||||||||||||||||||||||
| CATH/Gene3D | 2.60.40.10 (N/A) | ||||||||||||||||||||||||
| ChEMBL Target | CHEMBL1842 (Hs) |
关联配体
| Ligand ID | 6775 |
|---|---|
| 名称 | gemtuzumab ozogamicin |
| 别名 | Mylotarg® |
| 类别 | Antibody |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 | We have been unable to find publicly available affinity data for the interaction between gemtuzumab and CD33 to substantiate its primary molecular target. |
| 评价 |
This drug is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD33 +ve myeloid cells |
| 配体家族 | Immune checkpoint modulators |
| 单字母多肽序列 | |
| 三字母多肽序列 | |
| 翻译后修饰 | |
| 化学修饰 | |
| 临床描述 |
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with gemtuzumab may kill more cancer cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab in treating patients with newly diagnosed acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying combination chemotherapy and gemtuzumab to see how well they work compared with combination chemotherapy alone in treating young patients with newly diagnosed acute myeloid leukemia. |
| 来源公司 |
Children's Oncology Group |
参考文献
| 1. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.. Leukemia, 14 (3): (474-5). [PMID:10720144] |
产品问答
产品问答
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）